AKT1 modulators
By developing a pharmaceutical composition containing AKT1 inhibitors with specific structures, the problem of difficulty in effectively inhibiting the AKT1 signaling pathway in the prior art is solved, effective inhibition of cancer cell proliferation and survival is achieved, and new treatment plans are provided.
CN120225521APending Publication Date: 2025-06-27ALTEROME THERAPEUTICS INC
2 Cites 2 Cited by
Patent Information
- Application Number
- CN202380080404.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-09-14
- Filing Date
- 2023-09-25
- Publication Date
- 2025-06-27
AI Technical Summary
Technical Problem
The prior art is difficult to effectively inhibit the AKT1 signaling path, resulting in challenges in the treatment of diseases such as cancer.
Method used
A pharmaceutical composition containing a specific structure of AKT1 inhibitor was developed to inhibit the activity of AKT1, thereby interfering with its survival and proliferation signals in cells.
Benefits of technology
By inhibiting AKT1, it can effectively slow down the proliferation and survival of cancer cells and provide potential treatment options for diseases such as cancer.
✦ Generated by Eureka AI based on patent content.
Abstract
Provided herein are inhibitors of AKT1, pharmaceutical compositions comprising inhibitory compounds, and methods for treating diseases using AKT1 inhibitory compounds.
Need to check novelty before this filing date? Find Prior Art